GSK pays $70M to increase its access to Tempus patient data library

British multinational pharmaceutical and biotech corporation GSK declared a 3-yr arrangement with a $70 million initial payment to broaden its obtain to Tempus’ AI-run info library, including its de-determined patient data. 

GSK suggests the collaboration will allow for it to leverage the U.S.-primarily based company’s library to accelerate drug discovery in oncology, increase its clinical demo style and design, discover drug targets and pace up demo enrollment. 

Following a few yrs, GSK has the selection to prolong the settlement for an extra two years.  

The collaboration builds on GSK and Tempus’ present partnership targeted on scientific demo enrollment of individuals with particular cancer sorts, enabling GSK to access Tempus’ de-determined individual details specially. 

The providers are presently collaborating on an open-label stage II study, utilizing a information-pushed solution made to speed up research timelines. 

“This collaboration will deliver GSK with distinctive insights to discover improved medicines and renovate drug discovery. Tempus complements the get the job done our staff is currently executing at the intersection of genomics and machine studying throughout the two early discovery and clinical trials,” Tony Wood, main scientific officer at GSK, explained in a assertion.

THE Bigger Trend

GSK has partnered with many businesses in the earlier 12 months to increase its clinical exploration capabilities.   

In April of this year, GSK introduced a multiyear drug discovery partnership with AI-enabled pathology organization PathAI to progress clinical trials and drug growth in oncology and for nonalcoholic steatohepatitis (NASH). 

Earlier this year, GSK introduced it extended its drug discovery partnership with consumer genetics company 23andMe till July 2023. That collaboration started in 2018 when GSK delivered $300 million to the now publicly traded corporation.

Very last year, GSK expanded its partnership with Viome Lifestyle Sciences, a maker of at-dwelling checks for gut and immune program health and fitness. The alliance lets GSK to research the connection in between the intestine microbiome and some persistent ailments, like autoimmune ailments.